11-1299-42

antibody from Invitrogen Antibodies

Targeting: MPO

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

11-1299-42

Provider

Invitrogen Antibodies

Product name

Myeloperoxidase (MPO) Monoclonal Antibody (MPO455-8E6), FITC, eBioscience™

Antibody type

Monoclonal

Antigen

Other

Description

Description: The monoclonal antibody MPO455-8E6 recognizes myeloperoxidase (MPO), a protein within the azurophilic granules of myeloid cells. MPO is a multimeric protein comprised of two 55 kDa subunits and two 15 kDa subunits. The larger subunits associate with a heme protein resulting in a greenish color. As an enzyme, MPO breaks down hydrogen peroxide and oxidizes tyrosine. The products of this reaction, hypochlorous acid and tyrosyl radical, cause the cytotoxic and killing effects characteristic of neutrophils. Myeloperoxidase is important in the diagnosis of some cancers and increases in serum levels have been shown to correlate with cardiac events.

Conjugate

Green dye

Antibody clone number

MPO455-8E6

Concentration

5 µL/Test

References

Submitted references

Generation of Human Neutrophils from Induced Pluripotent Stem Cells in Chemically Defined Conditions Using ETV2 Modified mRNA.

Majumder A, Suknuntha K, Bennin D, Klemm L, Brok-Volchanskaya VS, Huttenlocher A, Slukvin I
STAR protocols 2020 Sep 18;1(2)

---

Loss of testosterone impairs anti-tumor neutrophil function.

Markman JL, Porritt RA, Wakita D, Lane ME, Martinon D, Noval Rivas M, Luu M, Posadas EM, Crother TR, Arditi M
Nature communications 2020 Mar 31;11(1):1613

---

The role of platelets in mediating a response to human influenza infection.

Koupenova M, Corkrey HA, Vitseva O, Manni G, Pang CJ, Clancy L, Yao C, Rade J, Levy D, Wang JP, Finberg RW, Kurt-Jones EA, Freedman JE
Nature communications 2019 Apr 16;10(1):1780

---

Targeting of Neutrophil Lewis X Blocks Transepithelial Migration and Increases Phagocytosis and Degranulation.

Brazil JC, Sumagin R, Cummings RD, Louis NA, Parkos CA
The American journal of pathology 2016 Feb;186(2):297-311

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Intracellular staining of normal human peripheral blood cells with Anti-Human CD3 APC (Product # 17-0036-42) and Mouse IgG1 K Isotype Control FITC (Product # 11-4714-42) (left) or Anti-Human Myeloperoxidase (MPO) FITC (right) using the Intracellular Fixation & Permeabilization Buffer Set (Product # 88-8824-00). Total cells were used for analysis.

Conjugate

Green dye

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 1 Characterization of human blood from influenza-infected patients. a - d Blood from influenza-infected patients was fixed after intravenous collection and stained as described in Methods. In all cases DNA was assessed by DAPI. a Many platelets appeared similar to those observed in control blood from healthy donors with a size of 2-5 um. b Some platelets from influenza-infected patients had undergone spreading with a distinctive distribution of CD41. c Platelets and platelet microparticles associated with DNA (arrow). d Spread platelets were found surrounding released DNA with distinct DNA content in their center. Of note, blood from influenza-infected patients and controls in ( a - d ) was not permeabilized. Since formaldehyde can cause certain levels of permeabilization as a function of cross-linking positive staining in control samples for H4 and MPO do not necessarily indicate activation. e - g Levels of proteins related to DNA release in the plasma of influenza-infected patients assessed by ELISA. Source data are provided as a Source Data file. e neutrophil elastase, f myeloperoxidase (MPO), and g histone nucleosome core. The graphs represent the average +- SD of healthy donors ( n = 15) and influenza-infected patients ( n = 18); significance for ( e - g ) was assessed by Mann-Whitney U test, star symbol (*) indicates p < 0.0001. h , i To synchronize time of influenza presence as a function of infection and quantify the released DNA, we

Conjugate

Green dye

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 5 Analysis of neutrophils from control or androgen deprivation therapy (ADT) treated patients. a Percent of circulating neutrophils from control or ADT treated prostate cancer patients that have a mature, segmented appearance morphologically. b Percent Cd11b + CD66b + CD16 lo neutrophils. c Percent myeloid derived suppressor cell (MDSC)-like neutrophils defined as HLA-DR - CD14 - CD33 + CD15 + . d Percent fold change in migration (percent crystal violet positive area of transwell stimulated with a chemoattractant divided by percent area without chemoattractant). e Percent of unstimulated neutrophils producing DHR123. f Percent of neutrophils producing DHR123 following PMA stimulation. g Percent myeloperoxidase + (MPO + ) neutrophils. h Percent of plated netosising neutrophils at 1 and 3 h following purification. Data in a - h are mean +- s.e.m., * p < 0.05, ** p < 0.01, *** p < 0.001 by multivariable linear regression using ADT as its main predictor and adjusting for presence of prostatectomy, age, race, and current status; control prostate cancer patients ( n = 8 in a , c , g and n = 7 in b , d , e , f , h ) and prostate cancer pati e nts receiving ADT ( n = 22 in a , c , g and n = 21 in b , d , e , f , h ).

Conjugate

Green dye

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 6 Induction of Neutrophil Formation from Myeloid Progenitors (A) Representative images of Wright stained cytospins showing the morphology of neutrophils. (B) Flow cytometric analysis of CD11b, CD15, CD16, CD66b, MPO and lactoferrin expression in generated neutrophils.

Conjugate

Green dye